Werewolf Therapeutics (NASDAQ:HOWL) Rating Reiterated by HC Wainwright

Werewolf Therapeutics (NASDAQ:HOWL)‘s stock had its “buy” rating reaffirmed by equities research analysts at HC Wainwright in a research note issued to investors on Tuesday, Benzinga reports. They presently have a $15.00 target price on the stock.

HOWL has been the subject of a number of other research reports. Wedbush reaffirmed an “outperform” rating and issued a $9.00 target price on shares of Werewolf Therapeutics in a research report on Monday, June 3rd. JMP Securities reaffirmed a “market outperform” rating and issued a $12.00 target price on shares of Werewolf Therapeutics in a research report on Wednesday, June 26th.

Werewolf Therapeutics Price Performance

Shares of NASDAQ HOWL opened at $2.14 on Tuesday. Werewolf Therapeutics has a twelve month low of $1.57 and a twelve month high of $8.19. The firm has a market cap of $92.99 million, a P/E ratio of -1.96 and a beta of 0.47. The company has a 50 day moving average of $4.26 and a 200 day moving average of $5.09. The company has a quick ratio of 6.71, a current ratio of 6.71 and a debt-to-equity ratio of 0.24.

Werewolf Therapeutics (NASDAQ:HOWL) last posted its earnings results on Friday, May 3rd. The company reported ($0.39) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.04). Werewolf Therapeutics had a negative return on equity of 36.15% and a negative net margin of 256.33%. The company had revenue of $0.74 million during the quarter, compared to the consensus estimate of $5.00 million. As a group, research analysts expect that Werewolf Therapeutics will post -1.52 EPS for the current fiscal year.

Institutional Investors Weigh In On Werewolf Therapeutics

Hedge funds have recently modified their holdings of the business. Financial Perspectives Inc grew its position in shares of Werewolf Therapeutics by 80.0% during the 4th quarter. Financial Perspectives Inc now owns 6,750 shares of the company’s stock valued at $26,000 after acquiring an additional 3,000 shares during the period. Certuity LLC bought a new position in Werewolf Therapeutics in the 4th quarter worth $39,000. Lighthouse Investment Partners LLC bought a new position in Werewolf Therapeutics in the 4th quarter worth $87,000. Denali Advisors LLC bought a new position in Werewolf Therapeutics in the 1st quarter worth $172,000. Finally, Acadian Asset Management LLC boosted its holdings in Werewolf Therapeutics by 119.8% in the 1st quarter. Acadian Asset Management LLC now owns 172,883 shares of the company’s stock worth $1,119,000 after buying an additional 94,212 shares during the period. Institutional investors own 64.84% of the company’s stock.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.